Scientist, Analytical Development-Bioassays (Temporary) at Vir Biotechnology

San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Bachelor's degree with 6+ years' of industry experience, Master's degree with 8+ years' of industry experience, or PhD with no industry experience
Experience in bioassay method development, transfer, and qualification
Experience in data analysis of bioassays including parallel line analysis and other statistical data analysis for evaluating method performance
Ability to execute laboratory experiments both independently and with other team members
Effective at troubleshooting method-related issues
Experience working on multiple projects, adjusting quickly to changes in priorities
Currently authorized to work for any employer in the U.S. (no sponsorship available)
Located in or able to work at San Francisco headquarters with at least 5 days per week in office

Responsibilities

Develop, optimize, and qualify cell-based and binding bioassays
Bring in new assay modalities and technology to the group as needed
Prepare assay standards, controls, critical reagents, and ensure appropriate system suitability criteria are met
Perform characterization testing including binding ELISA, neutralization assays, and effector function assays to support structure-function studies, forced degradation studies, and BLA-enabling process and formulation development studies
Troubleshoot method-related issues internally and at external labs
Author study protocols, development/qualification reports, and test methods; summarize and verify data for regulatory filings
Serve as subject matter expert for bioassays within the Product and Process Development department and the broader CMC organization
Support the development of bioassays to interrogate the mechanism of action for antibody and other biologic therapeutics
Execute cell-based and binding assays for characterization testing in support of process and formulation development, comparability, and structure-activity relationship studies
Design and conduct laboratory experiments

Skills

bioassays

cell-based assays

binding assays

ELISA

neutralization assays

effector function assays

assay development

assay optimization

assay qualification

troubleshooting

protocol authoring

characterization testing

Vir Biotechnology

Develops monoclonal antibodies for infectious diseases

About Vir Biotechnology

Vir Biotechnology develops treatments that leverage the immune system to combat infectious diseases. The company uses a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies, which aids in developing effective medicines. Their pipeline includes candidates for hepatitis B, hepatitis delta, HIV, and various viruses like influenza and COVID-19. Vir stands out by collaborating with industry leaders and organizations to accelerate scientific advancements, with the goal of transforming lives through innovative therapies.

San Francisco, CaliforniaHeadquarters

2016Year Founded

$640.6MTotal Funding

IPOCompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Risks

Leadership instability due to key executive resignations may disrupt operations.

Job cuts and facility closures indicate potential financial strain.

Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

Differentiation

Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.

The company focuses on immune system manipulation for targeted therapies.

Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Upsides

Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.

The rise of personalized medicine aligns with Vir's monoclonal antibody focus.

Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free